COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

The Promise Of Psilocybin When It Comes To Mental Health, And How COMPASS Pathways (NASDAQ: CMPS) Is Advancing It

October 12, 2023

By Faith Ashmore, Benzinga

Via TheNewswire.com

The Promise Of Psilocybin When It Comes To Mental Health, And How COMPASS Pathways (NASDAQ: CMPS) Is Advancing It

October 11, 2023

Recent advancements in understanding mental health and the brain have allowed us to identify possible commonalities between different mental health conditions. One of the shared experiences among...

Via Benzinga

Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More

October 06, 2023

Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares

Via Benzinga

Major Psychedelic Drug Stocks Continued To Decline This Week

October 06, 2023

A review of the performances of the 5 stocks in the Psychedelic Drug Stocks Index this week and since the end of August along with links to their latest news.

COMPASS Pathways Is Accelerating Patient Access To Evidence-Based Innovation In Mental Health Care

October 05, 2023

The Current Landscape Of Mental Health Is Failing Patients

Via Benzinga

Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More

October 02, 2023

Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of...

Via Benzinga

September Summary: Largest Psychedelic Drug Stocks Dropped 14%

October 01, 2023

Seelos Therapeutics' market capitalization dropped below $50M with the recent dramatic decline in its share price and, as such, is no longer part of the Psychedelic Drug Stocks Index. The remaining...

Psychedelic stocks should be part of a growth investor's portfolio due to the industry's ability to deliver strong return.

Don’t Miss the Boom: 3 Psychedelic Stocks Set to Explode Higher

September 27, 2023

Via InvestorPlace

Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More

September 26, 2023

Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge

Via Benzinga

Topics Economy

Psychedelic Drug Stocks Dragged Down By 83% Collapse In SEEL Stock Price

September 24, 2023

With the 82.6% collapse of Seelos Therapeutics (SEEL) last week, the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index declined by 13.0%, on average, and...

By Faith Ashmore, Benzinga

How COMPASS Pathways Is Leveraging AI To Revolutionize The Mental Healthcare Space

September 22, 2023

Via TheNewswire.com

Topics Artificial Intelligence

How COMPASS Pathways Is Leveraging AI To Revolutionize The Mental Healthcare Space

September 22, 2023

One Year Into Kabir Nath’s Leadership, Compass Pathways’ (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing

Topics Artificial Intelligence

September 19, 2023

By Faith Ashmore, Benzinga

Via TheNewswire.com

One Year Into Kabir Nath’s Leadership, Compass Pathways’ (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing

September 19, 2023

EQNX::TICKER_START (NYSE:JNJ),(NYSE:ABBV),(NASDAQ:ATAI),(NASDAQ:CMPS),(NASDAQ:MNMD) EQNX::TICKER_END

The Breakthrough Therapy Aiming To Solve The World’s Mental Health Crisis

September 19, 2023

Via FinancialNewsMedia

Topics Economy

Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More

September 18, 2023

Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next

Via Benzinga

One Year Into Kabir Nath's Leadership, Compass Pathways' (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing

September 18, 2023

Treatment-resistant depression, also referred to as TRD, is a subset of depression that poses significant challenges for clinicians, patients and those closest to patients. It is characterized by...

Via Benzinga

4 Of The 6 Largest Psychedelic Compound-Based R & D Stocks Had A Good Week

September 17, 2023

4 of the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index were up in price last week versus only 1 the previous week. The Index was up 2.4% for the week...

Swedish Foundation Supports Mental Health Innovation With New €3M Psychedelic Science Initiative

September 13, 2023

The Norrsken Foundation, a non-profit impact ecosystem “connecting founders with the capital, knowledge and network they need to make saving the world their business,” is launching a $3.22 (&e

Via Benzinga

What’s Spurring The Growth Of The Psychedelics Market – And How One Company Is Helping As Part Of The Vanguard In This Emerging Field

September 13, 2023

NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years

Topics Intellectual Property

September 12, 2023

NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035.

Via Benzinga

What's Spurring The Growth Of The Psychedelics Market – And How One Company Is Helping As Part Of The Vanguard In This Emerging Field

September 12, 2023

In August, a group of well-known biotech institutional investors participated in an up to almost $300 million financing round for COMPASS Pathways (NASDAQ: CMPS), consisting of an initial investment of...

Via Benzinga

Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More

September 11, 2023

Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification

Via Benzinga

Topics Artificial Intelligence

6 Largest Psychedelic Compound-Based R & D Stocks In Decline

September 10, 2023

The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 2.6%, on average, this week and are now only up 6.5% YTD.

Compass Pathways Explores AI-Powered Predictive Model On Psilocybin Therapy For Depression

September 06, 2023

COMPASS Pathways plc (NASDAQ: CMPS) shared the results from research on the potential of its novel AI technologies to support its proprietary COM

Via Benzinga

Topics Artificial Intelligence

6 Largest Psychedelic Compound-Based R & D Stocks Up 4%, On Average, Last Week

September 05, 2023

The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were UP 3.9%, on average, last week and are now only UP 9.4% YTD.

Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More

September 05, 2023

Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety

Via Benzinga

August Recap: Largest Psychedelic Compound-Based R & D Stocks Down 15%

September 02, 2023

The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 15.0%, on average, in August and are now only up 5.3% YTD.